Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alpha TeknovaTKNO +0.56%63 EBIT per Share is $-0.30 as of Mar. 2026. GuruFocus rates TKNO with a GF Score™ of 63/100 and a GF Value™ of $3.55 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 812 Drug Manufacturers companies, Alpha Teknova ranks better than 80.05% on this metric.
Alpha Teknova's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.08.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.30.
During the past 3 years, the average EBIT per Share Growth Rate was 32.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Alpha Teknova's EBIT per Share or its related term are showing as below:
TKNO'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -126.9 Med: 9.2 Max: 32.4
Current: 32.4
During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Alpha Teknova was 32.40% per year. The lowest was -126.90% per year. And the median was 9.20% per year.
TKNO's 3-Year EBIT Growth Rate is ranked better than 80.05% of 812
companies
in the Drug Manufacturers industry
Industry Median: 7.45
vs TKNO: 32.40
Alpha Teknova's EBIT for the
three
months ended in Mar. 2026 was $-4.29 Mil.
Alpha Teknova (NAS:TKNO) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Alpha Teknova EBIT per Share Related Terms
Alpha Teknova EBIT per Share Historical Data
* Premium members only.
The historical data trend for Alpha Teknova's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.30
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alpha Teknova (TKNO) has a EBIT per Share of $-0.30 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Alpha Teknova and its competitors. According to the industry distribution chart, Alpha Teknova ranks #162 out of 812 companies in the Drug Manufacturers industry, placing it in the top 20%.
Is Alpha Teknova's EBIT per Share too high?
Alpha Teknova's current EBIT per Share is $-0.30. Based on the distribution chart, Alpha Teknova ranks #162 out of 812 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Alpha Teknova has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alpha Teknova's EBIT per Share compare to AKBA and ORGO?
According to the Drug Manufacturers industry distribution chart, Alpha Teknova ranks #162 out of 812 companies for EBIT per Share. This places Alpha Teknova in the top 20% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 7.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.45, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Alpha Teknova and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alpha Teknova's current EBIT per Share is $-0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpha Teknova stock overvalued right now?
Based on GuruFocus' analysis, Alpha Teknova (TKNO) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.55, compared to a current price of $5.34 — trading 50.4% above its estimated fair value. The current EBIT per Share is $-0.30. Alpha Teknova's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Alpha Teknova (TKNO), the current EBIT per Share is $-0.30 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alpha Teknova (TKNO) Overvalued in 2026?
Based on GuruFocus' analysis, Alpha Teknova stock appears to be overvalued.
The current stock price of $5.34 is trading 50.4% above its estimated GF Value™ of $3.55.
GuruFocus considers Alpha Teknova to be Significantly Overvalued.
Key valuation signals for TKNO:
EBIT per Share: $-0.30
GF Value™: $3.55 vs. price of $5.34 (50.4% above fair value)
No single metric tells the full story. See the TKNO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.
63GF Score
Get the complete analysis for TKNO
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TKNO has been successfully added to your 
